Jason John Luke (Jason J Luke, Jason Luke)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 137

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal for immunotherapy of cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Muhammad Adnan Khattak, Jason John Luke
Top advances of the year: Melanoma. Cancer 130 (16) (2024)
Martin Wermke, Tobias A W Holderried, Jason John Luke, Van K Morris, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Ignacio I Wistuba, Edwin R Parra, Mohammad B Hossain, Sandra Grund-Gröschke, Katrin Aslan, Arun Satelli, Anantha Marisetty, Swapna Satam, Mamta Kalra, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Linus Backert, Melissa Baumeister, Sebastian Bunk, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Andrea Mayer-Mokler, Norbert Hilf, Delfi Krishna, Steffen Walter, Apostolia-Maria Tsimberidou, Cedrik M Britten
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. Journal for immunotherapy of cancer 12 (7) (2024)
Dirk Schadendorf, Jason John Luke, Paolo Antonio Ascierto, Georgina V Long, Piotr Lukasz Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for immunotherapy of cancer 12 (3) (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Martin Wermke, Tobias A W Holderried, Jason John Luke, Van K Morris, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Ignacio I Wistuba, Edwin R Parra, Mohammad B Hossain, Sandra Grund-Gröschke, Katrin Aslan, Arun Satelli, Anantha Marisetty, Swapna Satam, Mamta Kalra, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Linus Backert, Melissa Baumeister, Sebastian Bunk, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Andrea Mayer-Mokler, Norbert Hilf, Delfi Krishna, Steffen Walter, Apostolia-Maria Tsimberidou, Cedrik M Britten
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. Journal for immunotherapy of cancer 12 (7) (2024)
Kara M Schenk, Julie Stein Deutsch, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I Khushalani, Jason John Luke, Patrick A Ott, Jeffrey A Sosman, Vikram Aggarwal, Megan D Schollenberger, William H Sharfman, Kristin P Bibee, Jeffrey F Scott, Manisha J Loss, Hao Wang, Hanfei Qi, Elad Sharon, Howard Streicher, Helen X Chen, Robert N Woodward, Serena M Bagnasco, Janis M Taube, Suzanne L Topalian, Daniel C Brennan, Evan J Lipson
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, Jessica C Hassel, Alexandra Ikeguchi, Leonel Hernandez-Aya, Paul Nathan, Omid Hamid, Josep M Piulats, Matthew Rioth, Douglas B Johnson, Jason John Luke, Enrique Espinosa, Serge Leyvraz, Laura Collins, Chris Holland, Takami Sato
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Jason John Luke, Paolo Antonio Ascierto, Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Lukasz Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion Sileni, Joanne M Jeter, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S Carlino, Xi Lawrence Wu, Mizuho Kalabis, Clemens Krepler, Alexander M M Eggermont, Georgina V Long
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (14) (2024)
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, Jessica C Hassel, Alexandra Ikeguchi, Leonel Hernandez-Aya, Paul Nathan, Omid Hamid, Josep M Piulats, Matthew Rioth, Douglas B Johnson, Jason John Luke, Enrique Espinosa, Serge Leyvraz, Laura Collins, Chris Holland, Takami Sato
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Ryan C Augustin, Wesley L Cai, Jason John Luke, Riyue Bao
Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Elisa A Rozeman, Jason John Luke
The emergence of neoadjuvant immune-over BRAF therapy in melanoma. Cancer (2024)
Ryan C Augustin, Wesley L Cai, Jason John Luke, Riyue Bao
Facts and hopes in using omics to advance combined immunotherapy strategies. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Jason John Luke, Paolo Antonio Ascierto, Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Lukasz Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion Sileni, Joanne M Jeter, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S Carlino, Xi Lawrence Wu, Mizuho Kalabis, Clemens Krepler, Alexander M M Eggermont, Georgina V Long
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (14) (2024)
Mohamed K Abdelhakiem, Riyue Bao, Phillip M Pifer, David Molkentine, Jessica M Molkentine, Andrew Hefner, Beth Beadle, John V Heymach, Jason John Luke, Robert L Ferris, Curtis R Pickering, Jing H Wang, Ravi B Patel, Heath D Skinner
Th2 Cells Are Associated with Tumor Recurrence Following Radiation. Cancers 16 (8) (2024)
Ryan C Augustin, Wesley L Cai, Jason John Luke, Riyue Bao
Facts and hopes in using omics to advance combined immunotherapy strategies. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Jason John Luke, Diwakar Davar, Robert H Andtbacka, Nina Bhardwaj, Joshua D Brody, Jason A Chesney, Robert Coffin, Thierry de Baere, Tanja D de Gruijl, Matthew Fury, Gregory Goldmacher, Kevin J Harrington, Howard Kaufman, Ciara M Kelly, Anuradha D Khilnani, Ke Liu, Sherene Loi, Georgina V Long, Ignacio Melero Bermejo, Mark Ross Middleton, Bart Neyns, David James Pinato, Rahul A Sheth, Stephen B Solomon, Philippe Szapary, Aurélien Marabelle
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. Journal for immunotherapy of cancer 12 (4) (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Ryan C Augustin, Jason John Luke
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma. American journal of clinical dermatology 25 (3) (2024)
Ryan C Augustin, Wesley L Cai, Jason John Luke, Riyue Bao
Facts and hopes in using omics to advance combined immunotherapy strategies. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Ryan C Augustin, Wesley L Cai, Jason John Luke, Riyue Bao
Facts and hopes in using omics to advance combined immunotherapy strategies. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Kara M Schenk, Julie Stein Deutsch, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I Khushalani, Jason John Luke, Patrick A Ott, Jeffrey A Sosman, Vikram Aggarwal, Megan D Schollenberger, William H Sharfman, Kristin P Bibee, Jeffrey F Scott, Manisha J Loss, Hao Wang, Hanfei Qi, Elad Sharon, Howard Streicher, Helen X Chen, Robert N Woodward, Serena M Bagnasco, Janis M Taube, Suzanne L Topalian, Daniel C Brennan, Evan J Lipson
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (9) (2024)
Jason John Luke, Omid Hamid, Bernard A Fox, Paolo Antonio Ascierto, Iman Osman, James J Mule, Pedro J Romero, Michael T Lotze
Jeffrey S Weber, MD, PhD (1952-2024): in memoriam to discovery, friendship and family. Journal for immunotherapy of cancer 12 (9) (2024)
Nikhil I Khushalani, Patrick A Ott, Matthew J Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason John Luke, Ignacio Melero Bermejo, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (3) (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the therapeutic benefit of sequenced chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, Jessica C Hassel, Alexandra Ikeguchi, Leonel Hernandez-Aya, Paul Nathan, Omid Hamid, Josep M Piulats, Matthew Rioth, Douglas B Johnson, Jason John Luke, Enrique Espinosa, Serge Leyvraz, Laura Collins, Chris Holland, Takami Sato
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Jason John Luke, Diwakar Davar, Robert H Andtbacka, Nina Bhardwaj, Joshua D Brody, Jason A Chesney, Robert Coffin, Thierry de Baere, Tanja D de Gruijl, Matthew Fury, Gregory Goldmacher, Kevin J Harrington, Howard Kaufman, Ciara M Kelly, Anuradha D Khilnani, Ke Liu, Sherene Loi, Georgina V Long, Ignacio Melero Bermejo, Mark Ross Middleton, Bart Neyns, David James Pinato, Rahul A Sheth, Stephen B Solomon, Philippe Szapary, Aurélien Marabelle
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. Journal for immunotherapy of cancer 12 (4) (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Elisa A Rozeman, Jason John Luke
The emergence of neoadjuvant immune-over BRAF therapy in melanoma. Cancer (2024)
Yvonne M Mowery, Jason John Luke
NETosis Impact on Tumor Biology, Radiation, and Systemic Therapy Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Kara M Schenk, Julie Stein Deutsch, Sunandana Chandra, Diwakar Davar, Zeynep Eroglu, Nikhil I Khushalani, Jason John Luke, Patrick A Ott, Jeffrey A Sosman, Vikram Aggarwal, Megan D Schollenberger, William H Sharfman, Kristin P Bibee, Jeffrey F Scott, Manisha J Loss, Hao Wang, Hanfei Qi, Elad Sharon, Howard Streicher, Helen X Chen, Robert N Woodward, Serena M Bagnasco, Janis M Taube, Suzanne L Topalian, Daniel C Brennan, Evan J Lipson
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Muhammad Adnan Khattak, Jason John Luke
Top advances of the year: Melanoma. Cancer (2024)
Dirk Schadendorf, Jason John Luke, Paolo Antonio Ascierto, Georgina V Long, Piotr Lukasz Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for immunotherapy of cancer 12 (3) (2024)
Jason John Luke, Paolo Antonio Ascierto, Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Lukasz Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion Sileni, Joanne M Jeter, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S Carlino, Xi Lawrence Wu, Mizuho Kalabis, Clemens Krepler, Alexander M M Eggermont, Georgina V Long
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (14) (2024)
Mohamed K Abdelhakiem, Riyue Bao, Phillip M Pifer, David Molkentine, Jessica M Molkentine, Andrew Hefner, Beth Beadle, John V Heymach, Jason John Luke, Robert L Ferris, Curtis R Pickering, Jing H Wang, Ravi B Patel, Heath D Skinner
Th2 Cells Are Associated with Tumor Recurrence Following Radiation. Cancers 16 (8) (2024)
Ryan C Augustin, Wesley L Cai, Jason John Luke, Riyue Bao
Facts and hopes in using omics to advance combined immunotherapy strategies. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, Jessica C Hassel, Alexandra Ikeguchi, Leonel Hernandez-Aya, Paul Nathan, Omid Hamid, Josep M Piulats, Matthew Rioth, Douglas B Johnson, Jason John Luke, Enrique Espinosa, Serge Leyvraz, Laura Collins, Chris Holland, Takami Sato
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Ryan C Augustin, Wesley L Cai, Jason John Luke, Riyue Bao
Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Dirk Schadendorf, Jason John Luke, Paolo Antonio Ascierto, Georgina V Long, Piotr Lukasz Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for immunotherapy of cancer 12 (3) (2024)
Jason John Luke, Diwakar Davar, Robert H Andtbacka, Nina Bhardwaj, Joshua D Brody, Jason A Chesney, Robert Coffin, Thierry de Baere, Tanja D de Gruijl, Matthew Fury, Gregory Goldmacher, Kevin J Harrington, Howard Kaufman, Ciara M Kelly, Anuradha D Khilnani, Ke Liu, Sherene Loi, Georgina V Long, Ignacio Melero Bermejo, Mark Ross Middleton, Bart Neyns, David James Pinato, Rahul A Sheth, Stephen B Solomon, Philippe Szapary, Aurélien Marabelle
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. Journal for immunotherapy of cancer 12 (4) (2024)
Ryan C Augustin, Jason John Luke
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma. American journal of clinical dermatology (2024)
Ryan C Augustin, Jason John Luke
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma. American journal of clinical dermatology 25 (3) (2024)
Martin Wermke, Tobias A W Holderried, Jason John Luke, Van K Morris, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Ignacio I Wistuba, Edwin R Parra, Mohammad B Hossain, Sandra Grund-Gröschke, Katrin Aslan, Arun Satelli, Anantha Marisetty, Swapna Satam, Mamta Kalra, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Linus Backert, Melissa Baumeister, Sebastian Bunk, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Andrea Mayer-Mokler, Norbert Hilf, Delfi Krishna, Steffen Walter, Apostolia-Maria Tsimberidou, Cedrik M Britten
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. Journal for immunotherapy of cancer 12 (7) (2024)
Nikhil I Khushalani, Patrick A Ott, Matthew J Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason John Luke, Ignacio Melero Bermejo, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (3) (2024)
Ryan C Augustin, Wesley L Cai, Jason John Luke, Riyue Bao
Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, Jessica C Hassel, Alexandra Ikeguchi, Leonel Hernandez-Aya, Paul Nathan, Omid Hamid, Josep M Piulats, Matthew Rioth, Douglas B Johnson, Jason John Luke, Enrique Espinosa, Serge Leyvraz, Laura Collins, Chris Holland, Takami Sato
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. Journal for immunotherapy of cancer 12 (6) (2024)
Dirk Schadendorf, Jason John Luke, Paolo Antonio Ascierto, Georgina V Long, Piotr Lukasz Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for immunotherapy of cancer 12 (3) (2024)
Yvonne M Mowery, Jason John Luke
NETosis Impact on Tumor Biology, Radiation, and Systemic Therapy Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Mohamed K Abdelhakiem, Riyue Bao, Phillip M Pifer, David Molkentine, Jessica M Molkentine, Andrew Hefner, Beth Beadle, John V Heymach, Jason John Luke, Robert L Ferris, Curtis R Pickering, Jing H Wang, Ravi B Patel, Heath D Skinner
Th2 Cells Are Associated with Tumor Recurrence Following Radiation. Cancers 16 (8) (2024)
Jason John Luke, Paolo Antonio Ascierto, Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Lukasz Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion Sileni, Joanne M Jeter, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S Carlino, Xi Lawrence Wu, Mizuho Kalabis, Clemens Krepler, Alexander M M Eggermont, Georgina V Long
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Ryan C Augustin, Wesley L Cai, Jason John Luke, Riyue Bao
Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Nikhil I Khushalani, Patrick A Ott, Matthew J Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason John Luke, Ignacio Melero Bermejo, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (3) (2024)
Nikhil I Khushalani, Patrick A Ott, Matthew J Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason John Luke, Ignacio Melero Bermejo, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (3) (2024)
Paolo D A Vignali, Jason John Luke
Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (9) (2024)
Jason John Luke, Diwakar Davar, Robert H Andtbacka, Nina Bhardwaj, Joshua D Brody, Jason A Chesney, Robert Coffin, Thierry de Baere, Tanja D de Gruijl, Matthew Fury, Gregory Goldmacher, Kevin J Harrington, Howard Kaufman, Ciara M Kelly, Anuradha D Khilnani, Ke Liu, Sherene Loi, Georgina V Long, Ignacio Melero Bermejo, Mark Ross Middleton, Bart Neyns, David James Pinato, Rahul A Sheth, Stephen B Solomon, Philippe Szapary, Aurélien Marabelle
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease. Journal for immunotherapy of cancer 12 (4) (2024)
Dirk Schadendorf, Jason John Luke, Paolo Antonio Ascierto, Georgina V Long, Piotr Lukasz Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for immunotherapy of cancer 12 (3) (2024)
Jason John Luke, Paolo Antonio Ascierto, Muhammad A Khattak, Luis de la Cruz Merino, Michele Del Vecchio, Piotr Lukasz Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion Sileni, Joanne M Jeter, Caroline Robert, Jean-Jacques Grob, Federica de Galitiis, Dirk Schadendorf, Matteo S Carlino, Xi Lawrence Wu, Mizuho Kalabis, Clemens Krepler, Alexander M M Eggermont, Georgina V Long
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (14) (2024)
Nikhil I Khushalani, Patrick A Ott, Matthew J Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason John Luke, Ignacio Melero Bermejo, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 12 (3) (2024)
Ryan C Augustin, Jason John Luke
Top advances of the year: Melanoma. Cancer (2023)
Daniel J Olson, Jason John Luke
Myeloid maturity: ATRA to enhance anti-PD-1? Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jason John Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca S Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British journal of cancer (2023)
Lilit Karapetyan, Jason John Luke
Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (5) (2023)
Daniel J Olson, Jason John Luke
Myeloid maturity: ATRA to enhance anti-PD-1? Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Allison Betof Warner, Jason John Luke
CD4+ TIL to the rescue of anti-PD-1 failure by targeting MHC-II. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Ryan C Augustin, Jason John Luke
Top advances of the year: Melanoma. Cancer (2023)
Kari B Wisinski, Yael Flamand, Melissa A Wilson, Jason John Luke, Hussein A Tawbi, Fangxin Hong, Edith P Mitchell, James A Zwiebel, Helen Chen, Robert C Gray, Shuli Li, Lisa Meier McShane, Lawrence V Rubinstein, David R Patton, P Mickey Williams, Stanley R Hamilton, Robert J Behrens, Kathryn P Pennington, Barbara A Conley, Carlos L Arteaga, Lyndsay N Harris, Peter J O'Dwyer, Alice P Chen, Keith T Flaherty
Trametinib in Patients With NF1- , GNAQ- , or GNA11 -Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2. JCO precision oncology 7 (2023)
Ryan C Augustin, Jason John Luke
Top advances of the year: Melanoma. Cancer 129 (6) (2023)
Ryan C Augustin, Jason John Luke
Top advances of the year: Melanoma. Cancer 129 (6) (2023)
Jason John Luke, Manish R Patel, George R Blumenschein, Erika Paige Hamilton, Bartosz Chmielowski, Susanna V Ulahannan, Roisin M Connolly, Cesar A Santa-Maria, Jie Wang, Shakeela W Bahadur, Andrew Weickhardt, Adam S Asch, Girish Mallesara, Philip Clingan, Monika Dlugosz-Danecka, Monika Tomaszewska-Kiecana, Halyna Pylypenko, Nada Hamad, Hedy L Kindler, Bradley J Sumrow, Patrick Kaminker, Francine Z Chen, Xiaoyu Zhang, Kalpana Shah, Douglas H Smith, Anushka De Costa, Jonathan Li, Hua Li, Jichao Sun, Paul A Moore
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nature medicine (2023)
Richard A Miller, Jason John Luke, Shenshen Hu, Suresh Mahabhashyam, William B Jones, Thomas U Marron, Jaime R Merchan, Brett G M Hughes, Stephen B Willingham
Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. Journal for immunotherapy of cancer 10 (12) (2023)
Ryan C Augustin, Jason John Luke
Top advances of the year: Melanoma. Cancer 129 (6) (2023)
Richard A Miller, Jason John Luke, Shenshen Hu, Suresh Mahabhashyam, William B Jones, Thomas U Marron, Jaime R Merchan, Brett G M Hughes, Stephen B Willingham
Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. Journal for immunotherapy of cancer 10 (12) (2023)
Daniel J Olson, Jason John Luke
Myeloid maturity: ATRA to enhance anti-PD-1? Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Ryan C Augustin, Sarah Newman, Aofei Li, Marion Joy, Maureen Lyons, Mary P Pham, Peter Lucas, Katelyn Smith, Cindy Sander, Brian Isett, Diwakar Davar, Yana G Najjar, Hassane M Zarour, John M Kirkwood, Jason John Luke, Riyue Bao
Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. Journal for immunotherapy of cancer 11 (10) (2023)
Jason John Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca S Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British journal of cancer (2023)
Jason John Luke, Rebekah Dadey, Ryan Augustin, Sarah Newman, Krishna Singh, Rose Doerfler, Sarah Behr, Patrice Lee, Brian Isett, Christopher Deitrick, Aofei Li, Marion Joy, Carly Reeder, Katelyn Smith, Julie Urban, Lorenzo Sellitto, Mark Jelinek, Susan Christner, Jan Beumer, Liza Villaruz, Aditi Kulkarni, Diwakar Davar, Andrew Poklepovic, Yana Najjar, Dan Zandberg, Adam Soloff, Tullia C Bruno, Lazar Vujanovic, Heath Skinner, Robert Ferris, Riyue Bao
Tumor cell p38 inhibition to overcome immunotherapy resistance. Research square (2023)
Jason John Luke, Sarina A Piha-Paul, Theresa M Medina, Claire F Verschraegen, Mary Varterasian, Aoife M Brennan, Richard J Riese, Anna Sokolovska, James F Strauss, David L Hava, Filip Janku
Phase I study of SYNB1891, an engineered E coli Nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jason John Luke, Sarina A Piha-Paul, Theresa M Medina, Claire F Verschraegen, Mary Varterasian, Aoife M Brennan, Richard J Riese, Anna Sokolovska, James F Strauss, David L Hava, Filip Janku
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Xiaoran Zhang, Laura Ferris, Mark B Faries, Jason John Luke
Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Daniel J Olson, Jason John Luke
Myeloid maturity: ATRA to enhance anti-PD-1? Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Richard A Miller, Jason John Luke, Shenshen Hu, Suresh Mahabhashyam, William B Jones, Thomas U Marron, Jaime R Merchan, Brett G M Hughes, Stephen B Willingham
Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. Journal for immunotherapy of cancer 10 (12) (2023)
Lilit Karapetyan, Jason John Luke
Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (5) (2023)
Jason John Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca S Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British journal of cancer (2023)
Richard A Miller, Jason John Luke, Shenshen Hu, Suresh Mahabhashyam, William B Jones, Thomas U Marron, Jaime R Merchan, Brett G M Hughes, Stephen B Willingham
Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. Journal for immunotherapy of cancer 10 (12) (2023)
Richard C Wu, Jason John Luke
Uncovering the potential of CD40 agonism to enhance immune-checkpoint blockade. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
James W Smithy, Jason John Luke
CD16+ macrophages: an emerging biomarker for combined CTLA-4 and PD-1 blockade. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Ryan C Augustin, Riyue Bao, Jason John Luke
Targeting Cbl-b in cancer immunotherapy. Journal for immunotherapy of cancer 11 (2) (2023)
Jason John Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca S Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British journal of cancer (2023)
Rebecca Jane Lee, Jason John Luke
Potential of circulating tumor DNA to refine immunotherapy. Cancer (2023)
Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, Diwakar Davar, Geoffrey Thomas Gibney, Omid Hamid, Tina J Hieken, Benjamin Izar, Douglas B Johnson, Rajan P Kulkarni, Jason John Luke, Tara C Mitchell, Meghan J Mooradian, Krista M Rubin, April Ks Salama, Keisuke Shirai, Janis M Taube, Hussein A Tawbi, J Keith Tolley, Caressa Valdueza, Sarah A Weiss, Michael K Wong, Ryan J Sullivan
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal for immunotherapy of cancer 11 (10) (2023)
Ryan C Augustin, Jason John Luke
PD1 monotherapy reigns supreme in adjuvant melanoma…but for how long? Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Lilit Karapetyan, Jason John Luke
Interferon Biology and LAG-3 Shedding in PD-(L)1 plus LAG-3 Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 29 (5) (2023)
Ryan C Augustin, Riyue Bao, Jason John Luke
Targeting Cbl-b in cancer immunotherapy. Journal for immunotherapy of cancer 11 (2) (2023)
James W Smithy, Jason John Luke
CD16+ macrophages: an emerging biomarker for combined CTLA-4 and PD-1 blockade. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Aung Naing, John D Powderly, John J Nemunaitis, Jason John Luke, Aaron S Mansfield, Wells A Messersmith, Solmaz Sahebjam, Patricia M LoRusso, Ignacio Garrido-Laguna, Lance Leopold, Ryan Geschwindt, Kai Ding, Michael Smith, Jordan D Berlin
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. Journal for immunotherapy of cancer 10 (3) (2022)
Ryan C Augustin, Robert D Leone, Aung Naing, Lawrence Fong, Riyue Bao, Jason John Luke
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. Journal for immunotherapy of cancer 10 (2) (2022)
Lilit Karapetyan, Jason John Luke
Interferon biology and LAG3 shedding in PD-(L)1 plus LAG3 immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Jason John Luke, Fabrice Barlesi, Ki Chung, Anthony W Tolcher, Karen Kelly, Antoine Hollebecque, Christophe Le Tourneau, Vivek Subbiah, Frank Tsai, Steven Kao, Philippe A Cassier, Mustafa Khasraw, Hedy L Kindler, Hua Fang, Frances Fan, Kathryn Allaire, Maulik Patel, Shiming Ye, Debra T Chao, William R Henner, Joel S Hayflick, Michael A McDevitt, Lawrence Fong
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. Journal for immunotherapy of cancer 9 (2) (2022)
Richard D Carvajal, Paul D Nathan, Joseph J Sacco, Marlana Orloff, Leonel F Hernandez-Aya, Jessica Yang, Jason John Luke, Marcus O Butler, Sarah Stanhope, Laura Collins, Cheryl McAlpine, Chris Holland, Shaad E Abdullah, Takami Sato
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (17) (2022)

Jason John Luke.css-eqlu8i{font-size:small;padding-left:4px;} (Jason J Luke, Jason Luke)

Publication Activity (10 Years)

Top Topics

Top Venues

Jason John Luke (Jason J Luke, Jason Luke)